Background. Polysaccharide K, also known as PSK or Krestin, is derived from the Coriolus versicolor mushroom and is widely used in Japan as an adjuvant immunotherapy for a variety of cancer including lung cancer. Despite reported benefits, there has been no English language synthesis of PSK for lung cancer. To address this knowledge gap, we conducted a systematic review of PSK for the treatment of lung cancer. Methods. We searched PubMed, EMBASE, CINAHL, the Cochrane Library, AltHealth Watch, and the Library of Science and Technology from inception to August 2014 for clinical and preclinical evidence pertaining to the safety and efficacy of PSK or other Coriolus versicolor extracts for lung cancer. Results. Thirty-one reports of 28 studies were included for full review and analysis. Six studies were randomized controlled trials, 5 were nonrandomized controlled trials, and 17 were preclinical studies. Nine of the reports were Japanese language publications. Fifteen of 17 preclinical studies supported anticancer effects for PSK through immunomodulation and potentiation of immune surveillance, as well as through direct tumor inhibiting actions in vivo that resulted in reduced tumor growth and antimetastatic effects. Nonrandomized controlled trials showed improvement of various survival measures including median survival and 1-, 2-, and 5-year survival. Randomized controlled trials showed benefits on a range of endpoints, including immune parameters and hematological function, performance status and body weight, tumor-related symptoms such as fatigue and anorexia, as well as survival. Although there were conflicting results for impact on some of the tumorrelated symptoms and median survival, overall most randomized controlled trials supported a positive impact for PSK on these endpoints. PSK was safely administered following and in conjunction with standard radiation and chemotherapy. Conclusions. PSK may improve immune function, reduce tumor-associated symptoms, and extend survival in lung cancer patients. Larger, more rigorous randomized controlled trials for PSK in lung cancer patients are warranted.
Introduction
Lung cancer is the second most commonly diagnosed cancer, and the leading cause of cancer mortality resulting in approximately 150 000 deaths per year in the USA over the past decade. 1 More than 50% of lung cancer cases are diagnosed at the advanced stages of the disease, with poor prognosis and a 5-year survival rate less than 5%. 1 It is crucial to identify new adjuvant treatment strategies that might improve outcomes for this disease. Natural medicines are used by up to 54% of patients with lung cancer and deserve to be examined more closely for their potential to affect therapeutic outcomes as well as overall quality of life. 2 PSK, also known as polysaccharide K or Krestin, is a protein-bound polysaccharide or "proteoglycan" 3 that has been used in Japan for more than 30 years as an adjunctive immunotherapy for a variety of cancer types, including lung cancer. 3, 4 PSK was first isolated in 1971 from the mushroom Coriolus versicolor (also known as Trametes versicolor or Yun Zhi), and has since been studied in Japan for its effects when used in combination with standard surgery, chemotherapy, and radiation therapy. 3, 4 Controlled human trials have documented extended survival times associated with use of PSK in various cancer types, including breast, 5 colorectal, 6 and other gastrointestinal cancers, 7 but PSK has not been comprehensively reviewed for its effect in lung cancer specifically. 3 The structure of PSK consists of a polypeptide moiety to which polysaccharide β-d-glucan chains are attached; approximately 62% of the molecule is polysaccharide and 38% is protein. 3 PSP (polysaccharide peptide) is a closely related protein-bound polysaccharide derived from the same mushroom, and has also been studied for applications in cancer. The 2 polysaccharides are differentiated based on the presence of fucose in the PSK molecule, while rhamnose and arabinose are present in PSP; in other respects the 2 polysaccharides are chemically similar. 8 This review includes evidence for both PSK and PSP since both are Coriolus extracts.
Like interleukins, interferons, and colony stimulating factors, PSK is a nonspecific immunotherapy, meaning that it is used to "augment the body's natural immune response without directing it against any specific tumor antigen." 4 In the literature, PSK is also referred to as a biological response modifier, which is a substance that improves the "host versus tumor response" 4 and increases the ability of the host to defend itself from tumor progression. Immunologically, this may involve potentiation of natural killer (NK) cell and lymphocyte-activated killer (LAK) cell activity. 4 PSK may also be useful in offsetting some of the hematological side effects of chemotherapy such as leucopenia, thrombocytopenia, or pancytopenia.
Although promising results have been reported in clinical trials, there has been no knowledge synthesis of PSK or C versicolor for use in lung cancer. We conducted a systematic review of the safety and efficacy of PSK/C versicolor for the treatment and prevention of lung cancer.
Methods
We searched the following electronic databases for all levels of evidence pertaining to PSK and lung cancer: PubMed, EMBASE, CINAHL, AltHealthWatch, the Cochrane Library, and the National Library of Science and Technology, from inception to the end of October 2009. The PubMed search was updated to the end of August 2014. We used a broad-based MeSH and keyword approach combining clinical (lung cancer) and therapeutic (PSK) search terms. We hand searched bibliographies of review articles for additional references. Separate searches were conducted independently by the first and second authors (HF and DAK). Table 1 provides details on the search terms and strategy used to collect the records for screening from both searches employed. Figure 1 provides a flowchart of the searches.
We piloted data extraction forms in duplicate to assess inter-researcher reliability. On completion of data extraction in duplicate for fifty percent of human level studies, there were no major inconsistencies, and further duplication of data extraction was found to be redundant. Extraction sheets were prepared partly based on the Consolidated Standards of Reporting Trials (CONSORT) statement, 9, 10 the Newcastle-Ottawa scale (NOS), 11 and the Score for Assessment of Physical Experiments on Homeopathy (SAPEH) 12 for human trials, observational studies, and preclinical studies, respectively. For randomized controlled trials, quality assessment was performed according to the Jadad scoring system. 13 Screening of studies was initially conducted based on title review. In the event of uncertainty, abstracts and/or full texts were also reviewed. English language publications were included for all levels of evidence. Since the majority of human studies for PSK have been conducted in Japan, Japanese language publications were included if they reported controlled human trials; data for these was extracted by the third author (MI). Human trials had to assess the efficacy of PSK or other C versicolor preparations in lung cancer for the purposes of treatment, primary or secondary prevention, reduction of side effects and toxicities associated with chemotherapy or radiation therapy, or assessment of potential interactions with these therapies. All types of lung cancers (small cell lung cancer, non-small cell lung cancer, mesothelioma) were included.
For inclusion, preclinical studies had to be conducted in lung cancer models and examine either PSK or other C versicolor preparations for their anticancer effects or their interaction with conventional chemo-or radiation-therapy. Preclinical studies were categorized by results as positive, negative, neutral, or mixed. The term positive designates studies that found significant anticancer effects from PSK in models of lung cancer, alone or additively with other agents; negative designates studies that found significant procarcinogenic effects alone or in combination with other agents; and neutral designates studies that found neither significant beneficial effect nor any evidence of harm. In the absence of reported levels of significance, the authors' interpretation was used to guide classification. 
Results
The combined searches provided 214 records for screening. Fifteen reports of 11 controlled human trials 14-28 and 17 preclinical studies [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] were included in the efficacy analysis. One randomized controlled trial article also included the report of an animal study, for a total of 31 articles. Nine of the 15 reports were Japanese language publications. [18] [19] [20] [22] [23] [24] [25] [26] [27] Figure 1 shows a flowchart of the literature search and study selection.
Preclinical Evidence
Of the 17 included preclinical studies, 15 supported the anticancer effects of PSK. Two studies showed no significant effects and no studies found harmful or negative effects. Seven of the 17 supported immune mediated antitumor activity including tumor cell lysis by NK and LAK cells; seven supported antimetastatic activity; six supported anticancer effects in vivo by decreasing tumor size or incidence of cancer after carcinogen exposure; five supported the ability of PSK to increase survival in vivo; two studies supported antiproliferative effects; one study supported proapoptotic effects; and five supported general improvement in immune function by way of increased cell counts and cytokine levels as well as preventing chemotherapyinduced immune suppression. There was no evidence of PSK having a procarcinogenic effect. Table 2 summarizes the preclinical evidence. 21, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Immunologic Activity and Chemotherapy-Induced Immune Suppression. In vivo administration of PSK was able to abolish the decrease in phagoctyic activity and the number of Kupffer cells otherwise induced by the chemotherapeutic agents 1-2-tetrahydrofuryl-5-fluorouracil (FT) and 5-fluorouracil (5-FU). 41 In other lung cancer models, PSK increased the concentrations of lymphocytes, macrophages, and neutrophils in bronchoalveolar lavage fluid and induced synthesis of TNF-α, IL-1α, IL-6, MIP-1α, and MIP-1β 31 ; normalized splenic NK activity 33 ; and increased the numbers of CD8+ CD4− T cells and CD4+ CD8− T cells in the thymus. 39 Immune-Mediated Antitumor Activity. Ishihara et al, 32, 33 Ueno et al, 42 and Vanky et al, 44 found that PSK increased the antitumor cytotoxicity of various immune cells, including neutrophils, NK cells, and lymphocytes. PSK increased neutrophil mediated cytotoxicity and increased NK cell mediated lysis of tumor cells, prolonging survival and decreasing metastasis 32, 33 and increased the antitumor activity of splenic LAK cells and tumor infiltrating lymphocyte (TIL) cells. 42 In vitro, PSK at clinically attainable levels augmented the cytotoxicity of NK cells and large granular lymphocytes (LGLs) taken from lung cancer patients against various cancer cells. 37 Similar effects were found when using lymphocytes and target cancer cells taken from untreated lung (and other) cancer patients. 36 In animals, PSK administered within 48 hours of birth was found to significantly increase mean survival time up to 189% when animals were subsequently transplanted with lung cancer cells (P < .001); CD8+ T cells were thought to be the effector cells since blockade of CD8+ cell activity inhibited this effect. 39 Nonspecific Antitumor Effect. Ito et al 34 found that PSK reduced tumor growth in vivo, but mechanisms were not examined. Katoh and Ooshiro 38 found that PSK alone in high doses was able to inhibit lung tumor growth, but there was no additive effect in combination with uracil/tegafur/ leucovorin chemotherapy.
Metastasis. Ishihara et al 31 found that PSK given to a model of lung metastasis significantly reduced the number of lung nodules (P < .001) and increased the cytostatic activity of bronchoalveolar cells (P < .05) compared with controls. Further studies by the same team found similar effects, as well as reduced weight loss in the treated animals. 32, 33 Matsunaga et al 40 number of metastases and increased survival time compared with control animals (P < .05) through inhibition of tumor cell adhesion to membrane, degradation of collagen IV, chemotaxis of tumor cells, and haptotaxis to fibronectin. 40 In splenectomized animals treated with FT and 5-FU chemotherapy, PSK was able to offset the metastasis promoting effects of these drugs. 41 In combination with chemotherapy, PSK augmented the effect of cyclophosphamide and IL-2, suppressing lung metastasis, and increasing survival. 42 Following thoracic surgery, PSK nonsignificantly improved survival and decreased lung metastasis. 29, 30 When administered postoperatively with both surgical tumor removal and cyclophosphamide chemotherapy, PSK reduced lung metastasis compared with either cyclophosphamide or PSK alone. 43 Proliferation and Apoptosis. PSK significantly (P < .001) reduced proliferation of A549 lung cancer cells up to 80%; produced cell cycle arrest; increased the percentage of apoptotic cells in part by increasing expression of capsase 3; and increased peripheral blood lymphocyte (PBL) proliferation 4.5-fold over control (P < .01) when combined with IL-2. 35 
Nonrandomized Controlled Trials
There were eight reports of five nonrandomized controlled trials for the treatment of lung cancer. [16] [17] [18] 22, 23, [25] [26] [27] This category includes studies for which no randomization was reported as well as studies that explicitly stated that randomization was not used. Often the treating physician's clinical judgment as to which treatment would most benefit the particular patient was the deciding factor when choosing between several treatments, including chemotherapy alone, chemotherapy and PSK, chemotherapy and OK-432 (a bacterial-derived immunotherapy), or chemotherapy and both PSK and OK-432. In three of the five trials, PSK plus chemotherapy and/or radiation was compared with chemotherapy and/or radiation alone. In two trials, PSK was given without concurrent chemotherapy, and in one of these, PSK was given to stages I to III patients who had responded to previous radiation therapy. 16, 17 Median Survival. All five studies used measures of survival as endpoints. Significantly increased median survival was reported with use of PSK among stage 0 to 1 non-small cell lung cancer patients who had responded to radiation 16, 17 ; in patients receiving PSK, OK-432, or both as immunotherapy in addition to chemotherapy or radiation therapy. 23 One study found no difference between treatment with immunotherapy (PSK, OK-432, or Tegafur) plus chemotherapy compared to chemotherapy alone, 22 and one study reported increased median survival associated with use of PSK but did not provide a measure of significance for the finding. 18 One-, Two-, and Five-Year Survival. One study reported significantly increased 5-year survival in patients receiving PSK following radiotherapy compared with no adjunctive therapy, 30% compared with 9% (P < .001), and two studies failed to report significance. Other studies reported no significant effect for PSK alone, but significantly increased 1-year survival associated with combined use of both PSK and OK-432 compared with no adjunctive therapy (P < .025). 18 Ogawa et al [25] [26] [27] and Kawamura et al 22 reported increased survival at 1 and 2 years associated with use of either PSK or OK-432, or both, but did not report significance. Hayakawa et al 16, 17 found that use of PSK among patients with stage III disease increased their 2-year survival such that it was superior to that of stages I and II patients who received chemotherapy without PSK, 43% versus 26%, respectively (P < .05).
Randomized Controlled Trials
There were seven reports of six randomized controlled trials of PSK or PSP for the treatment of lung cancer. 14, 15, [19] [20] [21] 24, 28 All the randomized controlled trials involved administration of 3 g/d of PSK or PSP alongside standard chemotherapy, with the exception of the study by Tsang et al 28 during which PSP was given for 28 days following chemotherapy. All six studies showed benefit on at least one of the following endpoints: parameters of immune function, body weight, performance score, tumor-related symptoms, or survival. Tables 3 and 4 provide a description of the design and outcomes of the included studies. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Immune Function. PSK was found to shorten the duration of bone marrow suppression associated with chemotherapy, 20, 21 and beneficially increased white blood cell counts, 15, 21, 28 hemoglobin, 15 platelets, 21 neutrophils, 28 IgG and IgM, 28 NK cell activity, 14 IL-1, 14 IL-2, 15 and CD4/CD8 ratio and/or CD4 counts. 14, 15 Two of 3 studies found that PSP significantly increased or stabilized body weight compared with control patients receiving chemotherapy alone. 14, 15, 28 Performance Status and Body Weight. Two of three studies found that PSP or PSK was able to significantly improve performance status. 14, 15, 24 One study found no significant effect on tumor response rates or tumor-associated symptoms, but found that the PSK group had significantly fewer study withdrawals due to progressive disease, 5.9% compared with 23.5% in the control group (OR = 4.9, 95% CI = 1.0-25.5, P = .04). 28 Cancer-Associated Symptoms. Two of three studies found significant patient-reported improvements in tumor-related symptoms including fatigue, loss of appetite, nausea and vomiting, dry mouth and throat, spontaneous or night sweating, pain, palpitations and shortness of breath, insomnia, and anxiety, 14, 15 while the third study found no change for cough, dyspnea, pain, fatigue, or other symptoms. 28 Effectiveness. Three studies used a composite endpoint termed effectiveness or effectiveness rating; in one study, this term was not defined, 24 while in the other two studies treatment was considered "effective" if at least two of the following three criteria were met: (a) improved clinical symptoms, (b) stable or improved complete blood count or immunological parameters, and (c) improved performance status or body weight. 14, 15 Liu et al 14, 15 found an overall effectiveness rating in the range of 82% to 85% compared with approximately 45% in the placebo groups (P < .001 for both), 14 
Safety and Risks Associated With Use
No major adverse effects were reported in the studies reviewed above, including when PSK was administered to patients as long-term adjuvant therapy at a dose of 3 g daily for five or more years. 17 There are no known contraindications for use during chemotherapy or radiation therapy.
Coriolus has not been reported to affect clotting times. Some studies have reported no effect on platelet counts, while some report PSK offsetting the postchemotherapy decrease in platelets; however, there have been no reports of PSK decreasing platelet counts. 14, 15, 21, 28 Coriolus extracts may shorten or reduce the degree of immunosuppression associated with chemotherapy, without deleterious effects on liver or kidney function. 17, 28 
Discussion

Important Findings
These results suggest that PSK may significantly improve immune function, tumor-related symptoms, and survival in patients with lung cancer, when used as adjunctive therapy alongside or following standard chemotherapy or radiation therapy, or surgery. PSK appears to increase the tolerability of chemotherapy and reduce limiting factors such as bone marrow suppression, while improving long-term survival. PSK appears to be effective particularly among patients with earlier stages of disease, and has been shown to significantly improve survival among patients with stage I, II, and III disease. 19, 24 This notwithstanding, PSK has also been associated with improved survival of stage III patients when compared with stage II patients not receiving PSK. 16, 17 Mechanism PSK appears to exert its effects in large part through immune modulatory activity: increasing immune surveillance and offsetting chemotherapy induced bone marrow toxicity.
Preclinical and human level evidence shows that PSK is able to reduce the depression of immune cells and immune cell activity following chemotherapy. This includes NK and phagocytic activity; numbers of lymphocytes, macrophages, neutrophils in bronchoalveolar lavage fluid; numbers of CD4+ and CD8+ cells in the thymus; and blood counts of white blood cells, hemoglobin, platelets, neutrophils, immunoglobulins, CD4+ counts, and NK activity. Additional preclinical studies not related to lung cancer specifically show that PSK reduces tumor growth factor-β (TGF-β) and increases the antitumor response of peripheral blood mononuclear cells (PBMCs) to mitomycin-C (MMC)-treated cancer cells. 45 In addition, PSK was also able to enhance cytokine production (IL-2, IFN-γ, IL-4) in activated T-cells through activation of the T-cell receptor (TCR), 46 and enhanced the T-cell and splenocyte mitogenic response and macrophage tumoricidal activity. 47 Fisher and Yang 4 suggest that PSK activates a number of immunological pathways converging on cancer cell inhibition, including stimulating T-cell cytokine secretion; activating macrophages and increasing tissue macrophages presentation of tumor antigen; stimulating thymus and bone marrow activity, B-cell production of antitumor antibodies; increasing NK cell and cytotoxic T-cell activity; as well as exerting direct antitumor effects. This model is supported by our findings.
PSK also possesses direct chemopreventive activity, decreasing tumor growth in vivo, and antimetastatic effects, decreasing cancer cell chemotaxis and adhesion, as well as decreasing degradation of collagen IV. 32, [38] [39] [40] A recent 2012 review of the clinical and mechanistic anticancer effects of PSK found that the activity of PSK could be categorized in 3 ways. 48 First, PSK offsets immunosuppression induced by factors related to carcinogenesis, such as TGF-β, immunosuppressive acidic protein (IAP), prostaglandin E2 (PGE2), and IL-10, or as a result of cancer treatments, including surgery and chemotherapy. Second, PSK activates immune responses involved in antitumor effects, including maturation of dendritic cells (DCs) and activation of T cells, activation of NK cells, correction of Th1/Th2 imbalance, enhancement of B-cell antibody production, and promotion of IL-15 production by monocytes. Third, PSK enhances antitumor effects of chemotherapy by induction of apoptosis, inhibition of metastasis and neoangiogenesis, through direct actions on tumor cells.
Pharmacology
Pharmacokinetic studies have shown that PSK is partially digested in the gastrointestinal tract, and small molecular breakdown products are found in the bloodstream within two hours of ingestion. 4, 49 Larger substances consistent with intact PSK are observed with four hours of ingestion, suggesting that these are absorbed through a slower uptake process such as pinocytosis. 3, 4, 49 PSK is distributed extensively in bone marrow, salivary gland, brain, liver, spleen, and pancreas tissue, and is excreted primarily through pulmonary expiration (70%) as well as urine (15% to 20%) at 24 and 72 hours, respectively. 4, 50 
Drug Interactions and Contraindications
Given that PSP and PSK exert their influence via stimulation of the immune system, coadministration of these polysaccharides with immunosuppressant medication may negate their effect. 51 Furthermore, PSK and PSP may not be appropriate for individuals with autoimmune diseases or those receiving bone marrow transplants. 51 Few adverse effects have been reported with the use of PSK 3, 51 ; however, discoloration of the fingernails was noted in one study. 3, 52 There are no investigations directly assessing impact on the pharmacokinetics of chemotherapeutics alongside coadministration of PSK; however, findings from studies investigating adjuvant use or co-administration are not suggestive of harm.
Strengths and Limitations
Limitations of our review include the fact that only 54% of the human trials (six of 11) included were randomized, possibly contributing to introduction of bias among the results. These studies nonetheless provide additional controlled evidence of PSK's effects in a clinical setting. Some of the studies included are up to 30 years old. The standard of care for cancer patients has developed and improved cancer outcomes over this span of time. Despite recent advances, however, immunosuppression in particular remains a limiting factor in chemotherapy regimens, suggesting that use of PSK may remain relevant as an adjunctive therapy in lung cancer patients of varied stages. In addition, the benefit of immune stimulation may well exert important anticancer related activity. This is supported by a number of more recent studies corroborating the benefits of PSK. 16, 17, 20, 21, 28 Strengths of our review include its comprehensiveness in analyzing both English and Japanese language research, gray literature, as well as including preclinical level evidence. Future research should investigate the effects of PSK on survival, immune parameters, and cancer associated symptoms in a more rigorously designed clinical trial reflective of current practices.
The Coriolus extracts PSK and PSP appear to be safe and effective as long-term adjuvant immunotherapy in conjunction with or following standard chemotherapy and/or radiation, and may increase survival time, immune function, and tumor-associated symptoms in patients with lung cancer.
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